Cytokinetics (CYTK) Financial Analysis & Valuation | Quarter Chart
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle fu... more
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developi... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $8.51B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Robert I. Blum |
| IPO Date | 2004-04-26 | CAGR | — |
| Employees | 673 | Website | www.cytokinetics.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | -59.8% | Total Yield | -59.8% |
CYTK chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $10.98B | P/E | -8.48 | Forward P/E | -13.74 | PEG | — |
| P/S | 0.49 | P/B | -0.22 | P/CF | -0.05 | P/FCF | -0.05 |
| Sales | $70.96M | Sales 1Y | -17.24% | Sales 3Y | 613.02% | Sales 5Y | 22.77% |
| EPS | $-7.22 | EPS 1Y | 41.29% | EPS 3Y | 20.94% | EPS 5Y | 230.21% |
| Sales QoQ | 64.89% | EPS QoQ | -10.18% | Sales QoQ Avg | 198.47% | EPS QoQ Avg | 21.91% |
| Gross Margin | 84.97% | Operating Margin | -992.98% | Profit Margin | -1259.87% | ROCE | -40.42% |
| ROA | -46% | ROE | 164% | Altman Z Score | -0.99 | Piotroski Score | 1 |
| Current Ratio | 6.66 | Quick Ratio | 6.66 | Cash Ratio | 1.41 | Op. CF Ratio | -1.68 |
| Debt/Equity | -5.89 | Debt/Assets | 0.66 | Lt Debt/Equity | -7.04 | Lt Debt/Cap. | 1.22 |
| Intrst Cov. | -7.83 | Inventory Turnover | 28.06 | Asset Turnover | 0.04 | Receivables Turnover | 2.9 |
| Enterprise Value | $10.98B | P/E Ratio | -8.48 |
| Forward P/E | -13.74 | PEG Ratio | — |
| P/S Ratio | 0.49 | P/B Ratio | -0.22 |
| P/CF Ratio | -0.05 | P/FCF Ratio | -0.05 |
| EPS | $-7.22 | EPS Growth 1Y | 41.29% |
| EPS Growth 3Y | 20.94% | EPS Growth 5Y | 230.21% |
| Revenue Growth 1Y | -17.24% | Gross Margin | 84.97% |
| Operating Margin | -992.98% | Profit Margin | -1259.87% |
| ROE | 164% | ROA | -46% |
| ROCE | -40.42% | Current Ratio | 6.66 |
| Quick Ratio | 6.66 | Cash Ratio | 1.41 |
| Debt/Equity | -5.89 | Interest Coverage | -7.83 |
| Altman Z Score | -0.99 | Piotroski Score | 1 |
Cytokinetics (CYTK) valuation & financials
Cytokinetics (CYTK) has a market capitalization of $8.51B and trades at a price-to-earnings ratio of -8.5. It operates in the Healthcare sector (Biotechnology).
Cytokinetics's revenue grew -17.2% over the last year.
Cytokinetics's next earnings report is scheduled for November 4, 2026 after market close (provider scheduled date); analysts estimate EPS of $-1.45. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)